Compounds > 5'-iodoindirubin
Page last updated: 2024-12-07

5'-iodoindirubin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5'-iodoindirubin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124286
CHEMBL ID173445
CHEMBL ID1083838
SCHEMBL ID3849189
MeSH IDM0173377

Synonyms (15)

Synonym
nsc-717816
NCI60_040620
nsc717816
5'-iodoindirubin
(3z)-5-iodo-3-(3-oxoindolin-2-ylidene)indolin-2-one
5-iodo-3-(3-oxo-1,3-dihydro-2h-indol-2-ylidene)-1,3-dihydro-2h-indol-2-one
CHEMBL173445
5''-iodo-1h,1''h-[2,3'']biindolylidene-3,2''-dione
bdbm50313612
CHEMBL1083838 ,
126433-42-9
2h-indol-2-one, 3-(1,3-dihydro-3-oxo-2h-indol-2-ylidene)-1,3-dihydro-5-iodo-
3-(1,3-dihydro-3-oxo-2h-indol-2-ylidene)-1,3-dihydro-5-iodo-2h-indol-2-one
SCHEMBL3849189
2-(2-hydroxy-5-iodo-1h-indol-3-yl)indol-3-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase 17BHomo sapiens (human)IC50 (µMol)6.20000.02582.20726.2000AID1298193
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)IC50 (µMol)4.72200.00010.32759.5480AID463365
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
protein phosphorylationSerine/threonine-protein kinase 17BHomo sapiens (human)
apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 17BHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 17BHomo sapiens (human)
positive regulation of fibroblast apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
hemopoiesisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
leukocyte homeostasisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
myeloid progenitor cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
pro-B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of cell population proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
response to organonitrogen compoundReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine-mediated signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
animal organ regenerationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
common myeloid progenitor cell proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
regulation of apoptotic processReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAP kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAPK cascadeReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
lymphocyte proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein autophosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to cytokine stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to glucocorticoid stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
dendritic cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
multicellular organism developmentReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
protein kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
ATP bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
nuclear glucocorticoid receptor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein-containing complex bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
phosphatidylinositol 3-kinase activator activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
growth factor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
nucleusSerine/threonine-protein kinase 17BHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 17BHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentSerine/threonine-protein kinase 17BHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase 17BHomo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase 17BHomo sapiens (human)
Flemming bodySerine/threonine-protein kinase 17BHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17BHomo sapiens (human)
endoplasmic reticulumReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endoplasmic reticulum lumenReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endosome membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
receptor complexReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1461889Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by alamar blue assay
AID1298193Inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by ADP-Glo kinase assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.
AID463364Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
AID532592Therapeutic index, ration of TD50 for human foreskin fibroblast cell infected with Toxoplasma gondii to ID 50 for Toxoplasma gondii2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs.
AID532590Cytotoxicity against human foreskin fibroblast cell infected with Toxoplasma gondii2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs.
AID463363Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
AID73206Inhibition of glycogen synthase kinase-3-alpha/beta (GSK-3-alpha/beta) in porcine brain relative to indirubin2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
AID532591Antimicrobial activity against Toxoplasma gondii2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs.
AID463365Inhibition of FLT3 by HTRF assay2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
indirubin-3'-monoxime
indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.9740
indirubin-5-sulfonate
[no description available]		2.0410
cytarabine
[no description available]		2.0510beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
indirubin
[no description available]		2.9740
tryptanthrine
tryptanthrine: minor constituent of traditional Chinese medicine qing dai		2.0410alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound
lestaurtinib
[no description available]		2.0510indolocarbazole
5-iodoindirubin-3'-monoxime
5-iodoindirubin-3'-monoxime: inhibits GSK-3beta		2.7330
6-bromoindirubin-3'-oxime
6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.4320
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Myelogenous Leukemia
[description not available]		02.0510
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.0510
Carcinoma 256, Walker
A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)		01.9710
Experimental Leukemia
[description not available]		01.9710